FY25 Annual General Meeting MD & CEO’s Address

Open PDF
Stock Chrysos Corporation Ltd (C79.ASX)
Release Time 24 Nov 2025, 12:35 p.m.
Price Sensitive Yes
 Chrysos Corporation Ltd reports FY25 AGM MD & CEO's Address
Key Points
  • Delivered strong operational and financial performance in FY25
  • Expanded global footprint with new deployments and partnerships
  • Confident outlook for FY26 with reiterated revenue and EBITDA guidance
Full Summary

In FY25, Chrysos Corporation Ltd delivered strong operational and financial performance, expanding its global footprint, growing its installed base, and advancing its next-generation PhotonAssay technology. The company's performance remained robust, with healthy utilization levels and positive customer feedback on the reliability, speed, accuracy, and safety of its technology. Chrysos refined its deployment model, strengthened its supply chain, and continued to embed local technical and maintenance teams to ensure timely, on-the-ground support as it expanded its international footprint. The company's international momentum continued to build, with active deployments and partnerships across Australia, EMEA, and the Americas, firmly establishing Chrysos as a trusted partner to most of the world's leading gold miners and laboratories. The company's entry into South America through its partnership with Bureau Veritas was a particularly important step, unlocking growth opportunities in one of the world's largest gold mining regions. Looking ahead to FY26, the company reported a solid start to the year, with elevated industry activity and a strong flow-through of samples into its PhotonAssay units, particularly in Western Australia. Chrysos continues to achieve record sample volumes, which directly contribute to its revenue under its fee-per-sample model. The company reiterated its FY26 guidance of revenue between $80 to $90 million and EBITDA of between $20 to $27 million, and outlined its strategic priorities for the year ahead, including delivering on its contracted pipeline, deepening partnerships, enhancing operational efficiency and reliability, and advancing its technology roadmap.

Guidance

Chrysos Corporation Ltd reiterated its FY26 guidance of revenue between $80 to $90 million and EBITDA of between $20 to $27 million.

Outlook

Chrysos Corporation Ltd is confident in its outlook for FY26, supported by a buoyant gold market and a strong start to the year with elevated industry activity and a strong flow-through of samples into its PhotonAssay units.